Integrating Ctla-4/Pd-1 Blockade Into Cervical Cancer Management: Results of Compassion-16

Authors

Jeffrey A How
Amir A Jazaeri

Language

English

Publication Date

1-10-2025

Journal

Med

DOI

10.1016/j.medj.2024.11.011

PMID

39798550

PMCID

PMC11963253

PubMedCentral® Posted Date

1-10-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Although there is anti-tumor efficacy of dual CTLA-4/PD-1 blockade in advanced/recurrent cervical cancer, it is unclear whether combination with chemotherapy is synergistic. In COMPASSION-16, Wu et al. demonstrated improved survival outcomes of cadolinimab plus chemotherapy compared to chemotherapy alone for first-line systemic therapy for advanced/recurrent cervical cancer, suggesting a potential role of bispecific CTLA-4/PD-1 inhibitors in the frontline setting.

Keywords

Humans, Uterine Cervical Neoplasms, Female, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Neoplasm Recurrence, Local

Published Open-Access

yes

Recommended Citation

Jeffrey A How and Amir A Jazaeri, "Integrating Ctla-4/Pd-1 Blockade Into Cervical Cancer Management: Results of Compassion-16" (2025). Faculty, Staff and Student Publications. 5904.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5904